Janssen Biotech, Inc.

Centocor Ortho Biotech Inc.

Jarrat Jordan

Chichi Huang

Jinquan Luo

Ellen Chi

Ronald Swanson

Galina Obmolova

Christian Martinez

Xiefan Lin-Schmidt

Judith Ann Connor

Lu Lu

Jessica Schreiter

Marc Chevrier

Matteo Cesaroni

Robert T Sarisky

Bethany Swencki-Underwood

Sun-Yung Jung

Matthew Loza

Loqmane Seridi

Methods for administration of an anti-IFN-α/-ω antibody by subcutaneous or intravenous administration in a clinically proven safe amount are provided. Also provided are methods for clinically proven safe treatment of IFN-I mediated diseases, such as systemic lupus erythematosus (SLE), by subcutaneous or intravenous administration of an anti-IFN-α/-ω antibody.

Method of administration of an anti-IFN-α/-ω antibody

Type I interferon (IFN-I) signatures are useful in methods of diagnosing whether a subject (or patient) with IFN-I mediated disease will be responsive to treatment with an IFN-I inhibitor and treating or refraining from treating the subjects.

Type I interferon signatures and methods of use

Methods for selecting and treating patients with active Systemic Lupus Erythematosus (SLE) that are predicted to have an increased likelihood of having a positive response to a treatment with a safe and effective amount of an anti-IL-12/IL-23p40 antibody or an anti-IL-23 antibody, e.g., informs on what patients to treat with the anti-IL-12/IL-23p40 antibody ustekinumab.

Safe and effective method of treating lupus with anti-IL12/IL23 antibody

The present invention relates to antibodies that broady neutralize interferon-&#x3b1; and interferon-&#x3c9;, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.

Interferon alpha and omega antibody antagonists

Interferon &#x3b1; and &#x3c9; antibody antagonists

Broadly neutralizing interferon-&#x3b1; and interferon-&#x3c9; antibody antagonists, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing are useful in the treatment of diseases associated with increased production of IFN&#x3b1; and IFN&#x3c9;.

Agents interfering with translocation of Toll-like receptor 3 (TLR3), methods of making and using the foregoing are disclosed.

Methods for suppressing toll-like receptor activity

Cytokine IFN&#x3c9; nucleic acids from the Cynomolgus monkey are useful for expression of IFN&#x3c9; proteins that are functional homologs of human IFN&#x3c9;. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of IFN&#x3c9;, the generation and testing of IFN&#x3c9; modulators and related activities.

Monkey homolog of human interferon omega

Isolated polynucleotides encodingToll-Like Receptor 3 (Baboon TLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, and methods of use are disclosed.

Growing community of inventors

Spring House, PA, United States of America

Jarrat Jordan